Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Simple blood or urine test could spot kidney cancer early

NCT ID NCT06339138

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study collects blood, tissue, and urine from about 589 people with different types of kidney or urinary tract tumors, plus healthy volunteers. Researchers are looking for special DNA markers (methylated DNA) that could help detect these cancers earlier and more accurately. The goal is to develop a simple, non-invasive test using blood or urine samples.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

589 people

The number who actually took part.

Started

Jun 2018

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a histological diagnosis of primary clear cell RCC, papillary cell RCC, clear cell papillary RCC, chromophobe RCC, oncocytoma, urothelial cell carcinoma, or healthy participants who have undergone negative hematuria workups

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * CASE TISSUE: * Patient has a histological diagnosis of primary clear cell RCC, papillary cell RCC, clear cell papillary RCC, chromophobe RCC, oncocytoma, or urothelial cell carcinoma * Age \>= 18 years * CASE BLOODS AND URINE: * Patient has a histological diagnosis of primary clear cell RCC, papillary cell RCC, chromophobe RCC, oncocytoma, or urothelial cell carcinoma * Age \>= 18 years * HEALTHY CONTROL BLOODS AND URINE: * Patients has undergone negative hematuria workups (defined as negative abdominal imaging and negative cystoscopy * Age \>= 18 years Exclusion Criteria: * CASE TISSUE: * Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD) * The current target pathology is a recurrence * Patient has undergone any prior radiation therapy to target lesion prior to surgery * Patient has received chemotherapy class drugs in the 5 years prior to surgery * Patient has had any transplants prior to surgery * Patient has confirmation of Lynch Syndrome, is presumed to have Lynch Syndrome, or has familial cancer syndrome X * Patient has Nephritis (Glomerulus or Interstitial), Poly Cystic Kidney Disease, Glomerulonephropathies or Acquired Renal Kidney Disease * RENAL CONTROL TISSUE: * Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD). * Patient has inflammation, atypia, or hyperplasia of the parenchyma * Patient has a current or past history of renal cancer. * Patient has undergone any prior radiation therapy to target lesion prior to surgery * Patient has received chemotherapy class drugs in the 5 years prior to surgery * Patient has had any transplants prior to surgery * Patient has confirmation of Lynch Syndrome, is presumed to have Lynch Syndrome, or has familial cancer syndrome X * Patient has Nephritis (Glomerulus or Interstitial), Poly Cystic Kidney Disease, Glomerulonephropathies or Acquired Renal Kidney Disease * UROTHELIAL CONTROL TISSUE: * Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dubé syndrome (BHD) * Patient has inflammation, atypia, or hyperplasia of the urothelium * Patient has a current or past history of urothelial cancer * Patient has undergone any prior radiation therapy to target lesion prior to surgery * Patient has received chemotherapy class drugs in the 5 years prior to surgery * Patient has had any transplants prior to surgery * Patient has confirmed or presumed lynch * CASE BLOODS AND URINE: * Patient has known primary cancer outside of the kidney within the last 5 years prior to plasma and urine collection (not including basal cell or squamous cell skin cancers) * Patient has had surgery to completely or partially remove current target pathology * Patient has undergone any prior radiation therapy to target lesion prior to plasma and urine collection * Patient has received chemotherapy class drugs in the 5 years prior to plasma and urine collection * Patient has had any transplants prior to plasma and urine collection * Patient has confirmed or presumed lynch * Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dubé syndrome (BHD) * HEALTHY CONTROL BLOODS AND URINE: * Patient has known primary cancer outside of the urothelium within the last 5 years prior to plasma and urine collection (not including basal cell or squamous cell skin cancers) * Current target pathology is a recurrence * Patient has undergone prior radiation therapy in the 5 years prior to plasma and urine collection * Patient has received chemotherapy class drugs in the 5 years prior to plasma and urine collection * Patient has had any transplants prior to plasma and urine collection * Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD) * Patient has confirmed or presumed lynch * Gross urinary incontinence * Patient has undergone cystectomy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chromophobe renal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.